Weekly Companion Animal News: September 29, 2025

ELIAS publishes data on chemo-immunotherapy regimen for canine osteosarcoma

ELIAS Animal Health published data demonstrating that its chemo-immunotherapy regimen for canine osteosarcoma resulted in improved outcomes as compared to stand-alone chemotherapy using carboplatin. The study investigated a treatment strategy that integrates a single dose of chemotherapy followed by the ELIAS Cancer Immunotherapy (ECI) to enhance the immune system’s ability to recognize and destroy cancer cells.

Zomedica adds feline testing capability to TRUFORMA assay

Zomedica announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin & folate assay. “Feline patients with gastrointestinal disease often deteriorate more rapidly than canine patients, making timely and accurate results even more critical,” said researcher Deborah Greco, DVM, PhD, DACVIM.

Ensol Biosciences prepares to take canine osteoarthritis drug to US

South Korean biopharmaceutical company Ensol Biosciences announced it is preparing to take its animal osteoarthritis treatment drug – JointVex – global. JointVex is the first product launched as an animal medicine from the E1K ingredient, developed to inhibit inflammation in the joints while promoting cartilage regeneration. Since receiving government marketing approval in 2020, JointVex has been distributed by veterinary pharmaceutical company VEXPERT.

Felixvet generic drug for canine infections approved by FDA

Felixvet reports the FDA approved an oral lincosamide antibiotic, Clindamycin Hydrochloride Tablets, which is indicated to treat canine skin infections, deep wounds and abscesses, dental infections and osteomyelitis caused by susceptible bacterial strains. The drug has demonstrated activity against bacteria such as Staphylococcus aureus, Staphylococcus intermedius, Bacteroides fragilis and Clostridium perfringens.

Gallant one step closer to green light for stem cell therapy for cats with FCGS

Biotechnology company Gallant reported that the FDA agreed that the company’s uterine-derived allogeneic mesenchymal stromal cell therapy for cats with refractory feline chronic gingivostomatitis (FCGS) meets conditions for reasonable expectation of effectiveness (RXE), a requirement in the conditional approval process. If approved, the product would be the first FDA-approved ready-to-use stem cell therapy in veterinary medicine, according to Gallant.

Apoquel accidental overdoses rising in cats and dogs

The ASPCA and Pet Poison Hotline are reporting a rising trend in overdoses among dogs and cats of Apoquel Chewable, a flavored, chewable drug for skin allergies in dogs. Pets reportedly break into the packaging and gorging on the contents. Overdoses can result in vomiting, diarrhea, eye redness and swelling, and problems in the heart, kidneys and liver. Some animals have died.

Nutramax says Orlando will be site of 2026 ‘A Different Way to CE’

Nutramax Laboratories announced that the 2026 conference, “A Different Way to CE,” will again be hosted at the Gaylord Palms Orlando, September 9–12. New features for 2026 include case-based learning and interactive workshops, expanded CE topics, and a full lecture track designed for veterinary technicians. Nutramax will sponsor a party for attendees at Marvel Super Hero Island at Universal Islands of Adventure theme park.